Several studies suggest that probiotics might be useful in the management of atopic dermatitis (AD). However, the efficacy and comparison between both the administration of viable and non-viable probiotics on alleviation of AD is not well studied. Therefore, the purpose of this study was to evaluate the effect of L. sakei proBio65 live and dead cells when administered (1 × 10¹⁰ cells/day) for 12 weeks to children and adolescents (aged 3 to 18) with atopic dermatitis. In this randomized double-blind, placebo-controlled study, ninety patients were recruited and randomly allocated to either the L. sakei proBio65 live cells, L. sakei proBio65 dead cells, or placebo groups. Assessment of efficacy was based on the change in SCORing Atopic Dermatitis (SCORAD) score, Investigators Global Assessment (IGA) score, serum inflammatory markers such as the serum eosinophil (count), IgE, eosinophil cationic protein (ECP), CCL17 (thymus and activation-regulated chemokine [TARC]), and CCL27 (cutaneous T cell–attracting chemokine [CTACK]), and changes in skin condition (moisture and sebum) at baseline, week 6 and week 12. The SCORAD total score decreased in the live cells (p = 0.0015) and dead cell group (p = 0.0017) from the baseline after 12 weeks, whereas there were no significant changes in the placebo group when compared with baseline. The skin sebum content increased in both the live cell (p < 0.0001) and the dead cell group (p < 0.0001), suggesting potential improvements in skin barrier functions. Current data suggested a positive improvement in alleviation of AD symptoms upon oral administration of L. sakei proBio65 in both viable and non-viable forms.

几项研究表明，益生菌可能有助于治疗特应性皮炎 (AD)。然而，活性和非活性益生菌对缓解 AD 的疗效和比较尚未得到很好的研究。因此，本研究的目的是评估对患有特应性皮炎的儿童和青少年（3 至 18 岁）施用（1 × 10 ^{10 个}细胞/天）12 周后，日本清酒proBio65 活细胞和死细胞的效果。在这项随机双盲、安慰剂对照研究中，招募了 90 名患者并将其随机分配到L.sakei proBio65 活细胞或L.saseiproBio65 死细胞或安慰剂组。疗效评估基于 SCORing 特应性皮炎 (SCORAD) 评分、研究者全球评估 (IGA) 评分、血清炎症标志物如血清嗜酸性粒细胞（计数）、IgE、嗜酸性粒细胞阳离子蛋白（ECP）、CCL17（胸腺和激活调节趋化因子 [TARC]）和 CCL27（皮肤 T 细胞吸引趋化因子 [CTACK]），以及基线、第 6 周和第 12 周皮肤状况（水分和皮脂）的变化。 12 周后，细胞 ( p =  0.0015) 和死细胞组 ( p = 0.0017) 与基线相比有显着差异，而安慰剂组与基线相比没有显着变化。活细胞中的皮肤皮脂含量增加（p < 0.0001) 和死细胞组 ( p <  0.0001)，表明皮肤屏障功能的潜在改善。目前的数据表明，口服活体和非活体形式的清酒proBio65对 AD 症状的缓解有积极的改善。